STOCKHOLM–(BUSINESS WIRE)–Regulatory News: Tobii AB (Nasdaq Stockholm: TOBII) today reported its results for the third quarter of 2015. Continued good progress in all business units July – September · The Group’s sales totaled SEK 228 million (168), an increase of SEK 60 million or 36%, of which SEK 30 million was currency effects and SEK 30 million was organic growth. · Gross margin was 72% (71%). · The Group’s operating loss amounted to SEK -8 million (-21). · The combined operating profit
LAKE FOREST, Calif.–(BUSINESS WIRE)–ReVision Optics, Inc. (RVO), a leader in implantable presbyopia-correcting corneal inlay technology, announces that clinical data on the company’s Raindrop® Near Vision Inlay was published in the peer-reviewed Journal of Cataract Refractive Surgery. The Raindrop Inlay is a microscopic hydrogel inlay designed to improve near and intermediate vision, thus reducing the need for reading glasses. The article titled, “Range of refractive independence and mechanis
NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation today announced that it will report its third quarter 2015 financial results on Thursday, November 5, 2015.
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/3tp4c7/global_eyewear) has announced the addition of the “Global Eyewear Market Report: 2015 Edition” report to their offering. The global eyewear market consists…
東京–(BUSINESS WIRE)–（ビジネスワイヤ） — 株式会社ジェイアイエヌ（東京本社：東京都千代田区、代表取締役社長：田中仁）は、2015年11月5日（木）のJINS MEME一般発売に先駆け、11月3日（火・祝）13:00より東京・原宿のJINS MEMEフラッグシップストア原宿において50名様限定での(JINS MEME ES / JINS MEME MT）の先行発売イベントを行います。先行発売特典として度付レンズもしくはPCレンズへの無料交換対応を行うほか、オリジナル限定Tシャツをプレゼントいたします。 一般発売日の公開以降、かねてより発売を待ち望んでいた方々から多くの反響をいただいております。JINS MEMEの発売に期待を寄せる多くの皆様の気持ちに応えるために、JINS MEME専門店としてリニューアルするJINS MEMEフラッグシップストア原宿における数量限定先行発売を決定いたしました。 イベント概要 名 称 ： JINS MEME先行発売イベント 日 時 ： 2015年11月3日（火・祝）13:00より発売開始 場 所 ： JINS MEME フラッグ
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, plans to release third quarter 2015 financial results after the market close on Tuesday, November 10, 2015. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on Nov
DENVER–(BUSINESS WIRE)–Anthem Blue Cross and Blue Shield offers ‘New to Medicare’ Discount on Medicare Supplement Plan F in Colorado.
NEW YORK–(BUSINESS WIRE)–A study reports that wider adoption of “dropless” therapy in connection with cataract surgeries could save Medicare and Medicaid more than $7.1 billion over the next ten years.
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced topline results throug…
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, announced today topline efficacy results from a Phase 3 clinical trial to evaluate the safety and efficacy of DEXTENZA™ (sustained release dexamethasone) 0.4 mg, Intracanalicular Depot for the treatment of allergic conjunctivitis. DEXTENZA is a product candidate administered by a phy
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing and developing non-antibiotic antimicrobial products for the global eye care market, today announced that it intends to offer shares of its common stock and common stock purchase warrants in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be comple
NEWARK, California–(BUSINESS WIRE)–Oraya Therapeutics ha anunciado que la Sociedad alemana de oftalmología, la Sociedad de la Retina y la Asociación profesional de oftalmólogos alemanes, han emitido una opinión conjunta sobre el uso de la radioterapia junto con el sistema IRay® de radioterapia estereotáctica para la degeneración macular relacionada con la edad neovascular. El comunicado en el idioma original, es la versión oficial y autorizada del mismo. La traducción es solamente un medio de
NEWARK, Calif.–(BUSINESS WIRE)–Oraya Therapeutics heeft vandaag bekendgemaakt dat de Duitse Oogheelkundige Vereniging, de Retina Society en de Vereniging voor Duitse Oogheelkundigen een gezamenlijk oordeel over het gebruik van radiotherapie in combinatie met IRay® Stereotactic Radiotherapy System voor neovasculaire, leeftijdsgerelateerde maculadegeneratie. Dit oordeel geeft een richtlijn voor de selectie en behandeling van patiënten met bijkomende radiotherapie die ondergeschikt is aan therap
HOUSTON–(BUSINESS WIRE)–Eye Elegance recently opened the doors to their new second location at 1703 Post Oak Blvd. in the Galleria/Uptown Park area. On Wednesday, October 14th, VIP guests were invited to the new store.
LARGO, Fla.–(BUSINESS WIRE)–Ken Beckman, MD, President of CEDARS/ASPENS has stated, “We would like to extend our sincere thanks to Allergan, Bausch + Lomb, Shire, and Omeros for their annual support of CEDARS/ASPENS and for their enthusiasm and foresight in supporting the Society. These Annual Sponsorships as well as our Conference Sponsorships allow us to continue our work in shaping the future of anterior segment care through Innovation, Collaboration, and Education (I·C·E.) We look forward
NEEDHAM, Mass. & PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–Tyrogenex, a privately held biopharmaceutical company, today announced plans to present at the 14th Annual BIO Investor Forum in San Francisco on Wednesday, Oct. 21, 2015, at 9:30 a.m. PDT.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Eleven Biotherapeutics completed patient enrollment in its first pivotal, Phase 3 clinical study of isunakinra (EBI-005) in patients with moderate to severe allergic conjunctivitis.
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced the enrollment of the first patients in a third Phase 3 clinical trial for DEXTENZATM (sustained release dexamethasone) 0.4mg Intracanalicular Depot, for the treatment of post-surgical ocular inflammation and pain. Based on the results of the Company’s two previously c
ARLINGTON, Va.–(BUSINESS WIRE)–The CEA Foundation is pleased to announce the winners of its first “technology that improves lives” video contest. Aipoly, HelpAround, Los Angeles Low Vision, Perceptive Devices and WHILL were selected from more than 20…
STOCKHOLM–(BUSINESS WIRE)–Regulatory News: Tobii AB (STO:TOBII) plans to publish the interim report for the period January 1—September 30 on November 3 at 08.00 CET. Following this report Tobii will arrange a conference call with web cast presentation for investors, analysts and media. Tobii’s President and CEO Henrik Eskilsson and CFO Esben Olesen will present and comment on the report. After the presentation there will be time for questions. The presentation will be held in English. Time Tu